




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TRLATY (PCT)

(51) International Patent Classification ⁷ : C07C 405/00 // A61K 31/557		A1	(11) International Publication Number: WO 00/51979
			(43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number: PCT/US00/05299 (22) International Filing Date: 29 February 2000 (29.02.00) (30) Priority Data: 60/122,929 5 March 1999 (05.03.99) US (71) Applicant (for all designated States except US): THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DELONG, Mitchell, Anthony [US/US]; 8084 Tyler's Circle, West Chester, OH 45069 (US). SOPER, David, Lindsey [US/US]; 12075 Brisbane Place, Cincinnati, OH 45249 (US). WOS, John, August [US/US]; 8505 Harperpoint Drive, Cincinnati, OH 45249 (US). DE, Biswanath [US/US]; 11269 Cornell Woods Drive, Cincinnati, OH 45241 (US). (74) Agents: REED, T., David. et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: C₁₆ UNSATURATED FP-SELECTIVE PROSTAGLANDINS ANALOGS

(57) Abstract

The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R₁, X, and Z are defined below. This invention also includes optical isomers, diastereomers and enantiomers of said formula, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders using these compounds or the compositions containing them.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SI	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

C₁₆ UNSATURATED FP-SELECTIVE PROSTAGLANDINS ANALOGS

5


10

TECHNICAL FIELD

The subject invention relates to certain novel analogs of the naturally occurring prostaglandins. Specifically, the subject invention relates to novel Prostaglandin F analogs. The subject invention further relates to methods of using said novel Prostaglandin F analogs. Preferred uses include methods of treating bone disorders and glaucoma.

BACKGROUND OF THE INVENTION

20 Naturally occurring prostaglandins (PGA, PGB, PGE, PGF, and PGI) are C-20 unsaturated fatty acids. PGF_{2α}, the naturally occurring Prostaglandin F in humans, is characterized by hydroxyl groups at the C₉ and C₁₁ positions on the alicyclic ring, a cis-double bond between C₅ and C₆, and a trans-double bond between C₁₃ and C₁₄. Thus PGF_{2α} has the following formula:



25

Analogues of naturally occurring Prostaglandin F have been disclosed in the art. For example, see U.S. Patent No. 4,024,179 issued to Bindra and Johnson on May 17, 1977; German Patent No. DT-002,460,990 issued to Beck, Lerch, Seeger, and Teufel published on July 1, 1976; U.S. Patent No. 4,128,720 issued to Hayashi, Kori, and

30

Miyake on December 5, 1978; U.S. Patent No. 4,011,262 issued to Hess, Johnson, Bindra, and Schaaf on March 8, 1977; U.S. Patent No. 3,776,938 issued to Bergstrom and Sjoval on December 4, 1973; P.W. Collins and S. W. Djuric, "Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs", Chem. Rev. Vol. 93
5 (1993), pp. 1533-1564; G. L. Bundy and F. H. Lincoln, "Synthesis of 17-Phenyl-18,19,20-Trinorprostaglandins: I. The PG₁ Series", Prostaglandins, Vol. 9 No. 1 (1975), pp. 1-4; W. Bartman, G. Beck, U. Lerch, H. Teufel, and B. Scholken, "Luteolytic Prostaglandins: Synthesis and Biological Activity", Prostaglandins, Vol. 17 No. 2 (1979), pp. 301-311; C. Liljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell,
10 "Derivatives of 17- Phenyl-18,19,20-trinorprostaglandin F₂ α Isopropyl Ester: Potential Antiglaucoma Agents", Journal of Medicinal Chemistry, Vol. 38 No. 2 (1995), pp. 289-304.

Naturally occurring prostaglandins are known to possess a wide range of pharmacological properties. For example, prostaglandins have been shown to: relax
15 smooth muscle, which results in vasodilatation and bronchodilatation, to inhibit gastric acid secretion, to inhibit platelet aggregation, to reduce intraocular pressure, and to induce labor. Although naturally occurring prostaglandins are characterized by their activity against a particular prostaglandin receptor, they generally are not specific for any one prostaglandin receptor. Therefore, naturally-occurring prostaglandins are known to
20 cause side effects such as inflammation, as well as surface irritation when administered systemically. It is generally believed that the rapid metabolism of the naturally occurring prostaglandins following their release in the body limits the effects of the prostaglandin to a local area. This effectively prevents the prostaglandin from stimulating prostaglandin receptors throughout the body and causing the effects seen with the systemic
25 administration of naturally occurring prostaglandins.


Prostaglandins, especially prostaglandins of the E series (PGE), are known to be potent stimulators of bone resorption. PGF_{2 α} has also been shown to be a stimulator of bone resorption but not as potent as PGE₂. Also, it has been demonstrated the PGF_{2 α} has little effect on bone formation as compared to PGE₂. It has been suggested that
30 some of the effects of PGF_{2 α} on bone resorption, formation and cell replication may be mediated by an increase in endogenous PGE₂ production.

In view of both the wide range of pharmacological properties of naturally occurring prostaglandins and of the side effects seen with the systemic administration of these naturally occurring prostaglandins, attempts have been made to prepare analogs
35 to the naturally occurring prostaglandins that are selective for a specific receptor or receptors. A number of such analogs have been disclosed in the art. Though a variety

of prostaglandin analogs have been disclosed, there is a continuing need for potent, selective prostaglandin analogs for the treatment of a variety of diseases and conditions.

SUMMARY OF THE INVENTION

- 5 The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula:



wherein R₁, X, and Z are defined below.

- 10 This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof.

The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds.
 15 The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.

DETAILED DESCRIPTION OF THE INVENTION

20

Terms and Definitions

"Alkyl" is a saturated or unsaturated hydrocarbon chain having 1 to 18 carbon atoms, preferably 1 to 12, more preferably 1 to 6, more preferably still 1 to 4 carbon atoms. Alkyl chains may be straight or branched. Preferred branched alkyl have one or
 25 two branches, preferably one branch. Preferred alkyl are saturated. Unsaturated alkyl have one or more double bonds and/or one or more triple bonds. Preferred unsaturated alkyl have one or two double bonds or one triple bond, more preferably one double bond. Alkyl chains may be unsubstituted or substituted with from 1 to 4 substituents. Preferred substituted alkyl are mono-, di-, or trisubstituted. The substituents may be
 30 lower alkyl, halo, hydroxy, aryloxy (e.g., phenoxy), acyloxy (e.g., acetoxy), carboxy, monocyclic aromatic ring (e.g., phenyl), monocyclic heteroaromatic ring, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, and amino.

"Lower alkyl" is an alkyl chain comprised of 1 to 6, preferably 1 to 3 carbon atoms.

"Aromatic ring" is an aromatic hydrocarbon ring. Aromatic rings are monocyclic or fused bicyclic ring systems. Monocyclic aromatic rings contain from about 5 to about 10 carbon atoms, preferably from 5 to 7 carbon atoms, and most preferably from 5 to 6 carbon atoms in the ring. Bicyclic aromatic rings contain from 8 to 12 carbon atoms, preferably 9 or 10 carbon atoms in the ring system. Bicyclic aromatic rings include ring systems wherein one ring in the system is aromatic. Preferred bicyclic aromatic rings are ring systems wherein both rings in the system are aromatic. Aromatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred aromatic rings include naphthyl and phenyl. The most preferred aromatic ring is phenyl.

"Carbocyclic aliphatic ring" is a saturated or unsaturated hydrocarbon ring. Carbocyclic aliphatic rings are not aromatic. Carbocyclic aliphatic rings are monocyclic. Carbocyclic aliphatic rings contain from about 4 to about 10 carbon atoms, preferably from 4 to 7 carbon atoms, and most preferably from 5 to 6 carbon atoms in the ring. Carbocyclic aliphatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred carbocyclic aliphatic rings include cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. More preferred carbocyclic aliphatic rings include cyclohexyl, cycloheptyl, and cyclooctyl.

"Halo" is fluoro, chloro, bromo or iodo. Preferred halo are fluoro, chloro and bromo; more preferred are chloro and fluoro, especially fluoro.

"Haloalkyl" is a straight, branched, or cyclic hydrocarbon substituted with one or more halo substituents. Preferred haloalkyl are C₁-C₁₂; more preferred are C₁-C₆; more preferred still are C₁-C₃. Preferred halo substituents are fluoro and chloro. The most preferred haloalkyl is trifluoromethyl.

"Heteroalkyl" is a saturated or unsaturated chain containing carbon and at least one heteroatom, wherein no two heteroatoms are adjacent. Heteroalkyl chains contain from 1 to 18 member atoms (carbon and heteroatoms) in the chain, preferably 1 to 12, more preferably 1 to 6, more preferably still 1 to 4. Heteroalkyl chains may be straight or branched. Preferred branched heteroalkyl have one or two branches, preferably one branch. Preferred heteroalkyl are saturated. Unsaturated heteroalkyl have one or more double bonds and/or one or more triple bonds. Preferred unsaturated heteroalkyl have

one or two double bonds or one triple bond, more preferably one double bond. Heteroalkyl chains may be unsubstituted or substituted with from 1 to 4 substituents. Preferred substituted heteroalkyl are mono-, di-, or trisubstituted. The substituents may be lower alkyl, halo, hydroxy, aryloxy (e.g., phenoxy), acyloxy (e.g., acetoxy), carboxy, 5 monocyclic aromatic ring (e.g., phenyl), monocyclic heteroaromatic ring, monocyclic carbocyclic aliphatic ring, monocyclic heterocyclic aliphatic ring, and amino.

"Lower heteroalkyl" is a heteroalkyl chain comprised of 1 to 6, preferably 1 to 3 member atoms.

"Heteroaromatic ring" is an aromatic ring containing carbon and from 1 to about 4 10 heteroatoms in the ring. Heteroaromatic rings are monocyclic or fused bicyclic ring systems. Monocyclic heteroaromatic rings contain from about 5 to about 10 member atoms (carbon and heteroatoms), preferably from 5 to 7, and most preferably from 5 to 6 in the ring. Bicyclic heteroaromatic rings include ring systems wherein only one ring in the system is aromatic. Preferred bicyclic heteroaromatic rings are ring systems 15 wherein both rings in the system are aromatic. Bicyclic heteroaromatic rings contain from 8 to 12 member atoms, preferably 9 or 10 in the ring. Heteroaromatic rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo, haloalkyl, and phenyl. Preferred monocyclic 20 heteroaromatic rings include thienyl, thiazolo, purinyl, pyrimidyl, pyridyl, and furanyl. More preferred monocyclic heteroaromatic rings include thienyl, furanyl, and pyridyl. The most preferred monocyclic heteroaromatic ring is thienyl. Preferred bicyclic heteroaromatic rings include benzo[β]thiazolyl, benzo[β]thiophenyl, quinolinyl, quinoxalinyl, benzo[β]furanyl, benzimidazolyl, benzoxazolyl, indolyl, and anthranilyl. 25 More preferred bicyclic heteroaromatic rings include benzo[β]thiazolyl, benzo[β]thiophenyl, and benzoxazolyl.

"Heteroatom" is a nitrogen, sulfur, or oxygen atom. Groups containing more than one heteroatom may contain different heteroatoms.


"Heterocyclic aliphatic ring" is a saturated or unsaturated ring containing carbon 30 and from 1 to about 4 heteroatoms in the ring, wherein no two heteroatoms are adjacent in the ring and no carbon in the ring that has a heteroatom attached to it also has a hydroxyl, amino, or thiol radical attached to it. Heterocyclic aliphatic rings are not aromatic. Heterocyclic aliphatic rings are monocyclic. Heterocyclic aliphatic rings contain from about 4 to about 10 member atoms (carbon and heteroatoms), preferably 35 from 4 to 7 member atoms, and most preferably from 5 to 6 member atoms in the ring. Heterocyclic aliphatic rings may be unsubstituted or substituted with from 1 to 4

substituents on the ring. The substituents may be halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents include halo and haloalkyl. Preferred heterocyclic aliphatic rings include piperzyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl and piperdyl.

- 5 "Phenyl" is a monocyclic aromatic ring which may or may not be substituted with from about 1 to about 4 substituents. The substituents may be fused but not bridged and may be substituted at the *ortho*, *meta* or *para* position on the phenyl ring, or any combination thereof. The substituents may be halo, acyl, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, phenoxy or any combination thereof. Preferred substituents on the
10 phenyl ring include halo and haloalkyl. The most preferred substituent is halo. The preferred substitution pattern on the phenyl ring is *ortho* or *meta*. The most preferred substitution pattern on the phenyl ring is *meta*.

Compounds

- 15 The subject invention involves compounds having the following structure:



Formula A

- 20 In the above structure, R_1 is CO_2H , $\text{C}(\text{O})\text{NHOH}$, CO_2R_2 , CH_2OH , $\text{S}(\text{O})_2\text{R}_2$, $\text{C}(\text{O})\text{NHR}_2$, $\text{C}(\text{O})\text{NHS}(\text{O})_2\text{R}_2$, or tetrazole; wherein R_2 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring and R_3 is lower alkyl, lower heteroalkyl, or haloalkyl. Preferred R_2 is methyl, ethyl, and isopropyl. Preferred R_1 is CO_2H , $\text{C}(\text{O})\text{NHOH}$, CO_2R_2 ,
25 $\text{C}(\text{O})\text{NHS}(\text{O})_2\text{R}_2$, and tetrazole. Most preferred R_1 is CO_2H and CO_2R_2 .

In the above structure, X is $\text{CH}=\text{C}=\text{CH}$, $\text{CH}=\text{CH}$, $\text{CH}=\text{N}$, $\text{C}(\text{O})$, or $\text{C}(\text{O})\text{Y}$; wherein Y is O, S, or NH. Preferred X is $\text{CH}=\text{C}=\text{CH}$, $\text{CH}=\text{N}$, $\text{C}(\text{O})$, and $\text{C}(\text{O})\text{Y}$. X is not part of an aromatic or heteroaromatic ring system.

- In the above structure, Z is an aromatic ring or a heteroaromatic ring provided
30 that when Z is a heteroaromatic ring Z is attached via a Carbon member atom. Preferred Z is monocyclic aromatic ring. More preferred Z is furanyl, thienyl, and phenyl.

The invention also includes optical isomers, diastereomers and enantiomers of the above structure. Thus, at all stereocenters where stereochemistry is not defined (C_{11} , C_{12} , and C_{15}), both epimers are envisioned. Preferred stereochemistry at all such stereocenters of the compounds of the invention mimic that of naturally occurring $PGF_{2\alpha}$.

5 It has been discovered that the novel PGF analogs of the subject invention are useful for treating bone disorders, especially those that require a significant increase in bone mass, bone volume, or bone strength. Surprisingly, the compounds of the subject invention have been found to provide the following advantages over known bone disorder therapies: (1) An increase trabecular number through formation of new
10 trabeculae; (2) An increase in bone mass and bone volume while maintaining a more normal bone turnover rate; and/or (3) An increase in bone formation at the endosteal surface without increasing cortical porosity.

In order to determine and assess pharmacological activity, testing of the subject compounds in animals is carried out using various assays known to those skilled in the
15 art. For example, the bone activity of the subject compounds can be conveniently demonstrated using an assay designed to test the ability of the subject compounds to increase bone volume, mass, or density. An example of such assays is the ovariectomized rat assay.


In the ovariectomized rat assay, six-month old rats are ovariectomized, aged 2
20 months, and then dosed once a day subcutaneously with a test compound. Upon completion of the study, bone mass and/or density can be measured by dual energy x-ray absorptometry (DXA) or peripheral quantitative computed tomography (pQCT), or micro computed tomography (mCT). Alternatively, static and dynamic histomorphometry can be used to measure the increase in bone volume or formation.

25 Pharmacological activity for glaucoma can be demonstrated using assays designed to test the ability of the subject compounds to decrease intraocular pressure. Examples of such assays are described in the following reference, incorporated herein: C. Liljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell, "Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin $F_{2\alpha}$ Isopropyl Ester: Potential Antiglaucoma
30 Agents", Journal of Medicinal Chemistry, Vol. 38 No. 2 (1995), pp. 289-304.

Compounds useful in the subject invention can be made using conventional organic syntheses. Particularly preferred syntheses are carried out using the following general reaction schemes, **Schemes I, II, and III**. **Scheme I** describes a general reaction scheme for making compounds of the invention wherein X is $CH=CH$ (**Formula I**) or $CH=C=CH$ (**Formula II**). **Scheme II** describes a general reaction scheme for
35 making compounds of the invention wherein X is $C(O)$ (**Formula III**) or $C(O)Y$ (**Formula**

IV). **Scheme III** describes a general reaction scheme for making compounds of the invention wherein X is CH=N (**Formula V**).

Scheme 1



In **Scheme 1**, R₁ and Z are as defined above. The methyl 7-[3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl] heptanoate (**S1a**) depicted as starting material for **Scheme 1** is commercially available (such as from Sumitomo Chemical or Cayman Chemical).

In the above **Scheme 1**, Methyl 7-[3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl] heptanoate (**S1a**) is reacted with a silylating agent and base in a solvent that will allow the silylation to proceed. Preferred silylating agents include *tert*-butyldimethylsilyl chloride and *tert*-butyldimethylsilyl trifluoromethanesulphonate. The most preferred silylating agent is *tert*-butyldimethylsilyl trifluoromethanesulphonate. Preferred bases include triethylamine, trimethylamine, and 2,6-lutidine. More preferred bases include

triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature preferably between -100°C and 100°C, more preferably between -80°C and 80°C, and most preferably between -70°C and 23°C.

The resulting silylated compound is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum.

The silylated compound is then reacted with the cuprate generated via Grignard formation of the appropriate alkenyl bromide as disclosed, for example, in the following references: H.O. House et. al., "The Chemistry of Carbanions: A Convenient Precursor for the Generation of Lithium Organocuprates", J. Org. Chem. Vol. 40 (1975) pp. 1460-69 ; and P. Knochel et. al., "Zinc and Copper Carbenoids as Efficient and Selective α 'd' Multicoupling Reagents", J. Amer. Chem. Soc. Vol. 111 (1989) p. 6474-76. Preferred alkenyl bromides include 4-bromo-1-butene, 4-bromo-1-butyne, 4-bromo-2-methyl-1-butene, and 4-bromo-2-ethyl-1-butene. The most preferred alkenyl bromide is 4-bromo-1-butene. Preferred solvents include ethereal solvents, of which diethyl ether and tetrahydrofuran are preferred. The most preferred solvent is tetrahydrofuran. The Grignard reagent is allowed to form at a temperature between 100°C and 23°C, more preferably between 85°C and 30°C, and most preferably between 75°C and 65°C. The reaction time is preferably between 1 hour and 6 hours, with a more preferred reaction time being between 2 hours and 5 hours, and the most preferred reaction time being between 3 hours and 4 hours.

Once the Grignard reagent is formed, the cuprate is generated from the alkenyl magnesium species. The temperature range for cuprate formation is between -100°C and 0°C. The preferred temperature range is between -80°C and -20°C. The more preferred temperature range is between -75°C and -50°C. The preferred reaction time is between 30 minutes and 6 hours. The more preferred reaction time is between 45 minutes and 3 hours. The most preferred reaction time is between 1 hours and 1.5 hours.

The alkene thus formed is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the alkene is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 10% EtOAc/hexanes as the eluent. The alkene is then reacted with a hydride reducing agent and a polar, protic solvent to give

the C-9 alcohol. Preferred reducing agents include lithium aluminum hydride, sodium borohydride, and L-selectride. More preferred reducing agents include sodium borohydride, and L-selectride. The most preferred reducing agent is sodium borohydride. Preferred solvents include methanol, ethanol, and butanol. The most preferred solvent is methanol. The reduction is carried out at a temperature between -100°C and 23°C. The preferred temperature range is between -60°C and 0°C. The most preferred temperature range is between -45°C and -20°C.

The resulting alcohol is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the alcohol is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

The resultant alcohol can be protected as described previously herein. Preferred silylating agents in this case also include *tert*-butyldimethylsilyl chloride and *tert*-butyldimethylsilyl trifluoromethanesulfonate. The most preferred silylating agent is *tert*-butyldimethylsilyl trifluoromethanesulfonate. Preferred bases include triethylamine, trimethylamine, and 2,6-lutidine. More preferred bases include triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature preferably between -100°C and 100°C, more preferably between -80°C and 80°C, and most preferably between -70°C and 23°C.

The resulting silylated compound, **S1b** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum, giving compound **S1b**.

The protected alcohol is then treated with a form of osmium and sodium periodate in a solvent where they are both soluble. Preferred forms of osmium include osmium tetroxide and potassium osmate. Preferred solvent systems include 1:1 mixtures of acetic acid and water and 1:1:2 mixtures of water, acetic acid and THF. The result of this treatment is the aldehyde, **S1c**.


The compound **S1c** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, **S1c** is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

The key intermediate aldehyde depicted as **S1c** can be reacted with a variety of unsaturated alkenyl anion nucleophiles to provide the C-9 and C-11-protected 13,14-dihydro-prostaglandin $F_{1\alpha}$ derivatives.

The resulting compounds can be isolated, but are generally deprotected using techniques known to one of ordinary skill in the art, and optionally, manipulated at C-1 to provide the desired acid derivative at R_1 . For example, the condensation of a methyl ester with an amine or a hydroxylamine provides an amide or a hydroxamic acid compound, respectively. After any such manipulation at C-1, the compounds are isolated as the final 13,14-dihydro-15-substituted-15-pentanor prostaglandin $F_{1\alpha}$ derivative, **Formula I**.
10 Compounds depicted by **Formula I** are exemplified in **Examples 1-12, 18, and 20**.

Compounds depicted by **Formula II** can be made directly from intermediate **S1c** in a manner similar to that for compounds depicted by **Formula I** substituting the appropriate allene anion. With allene nucleophiles, the reaction is carried out preferably at between -80°C and 0°C, more preferably between -80°C and -20°C, and most preferably between -80°C and -40°C. Preferred bases for the reaction include *n*-butyl lithium, *s*-butyl lithium, and *t*-butyl lithium. The most preferred base is *n*-butyl lithium. Preferred solvents for the reaction are ether solvents. Preferred solvents include diethyl ether, and tetrahydrofuran. The most preferred solvent is tetrahydrofuran. With heterocyclic nucleophiles, preferred solvents include ethereal solvents. More preferred ethereal solvents include diethyl ether, dibutyl ether and tetrahydrofuran. The most preferred ethereal solvent is tetrahydrofuran. After isolation, similar C-1 manipulations and/or deprotection of the functional groups ensues using techniques known to one of ordinary skill in the art. Compounds depicted by **Formula II** are exemplified in **Examples 13-17 and 19**.
15
20

Scheme II



- 5 In **Scheme 2**, R_1 , Y, and Z are as defined above. The protected alcohol **S1b** (from **Scheme 1**) is treated with a hydroborating reagent in an ethereal solvent, followed by oxidative removal of the boron reagent with a suitable oxidant to give a compound of the type **S2a**. Preferred hydroborating reagents include monochloroborane-dimethylsulfide, diborane, borane-tetrahydrofuran and borane-dimethylsulfide. The most
- 10 preferred hydroborating reagent is borane-dimethylsulfide. Preferred ethereal solvents include THF and diethyl ether. The most preferred solvent is THF. The reaction is carried out from about 1 to about 24 hours at a temperature of from about $-20\text{ }^{\circ}\text{C}$ to about $+30\text{ }^{\circ}\text{C}$. The preferred temperature range is from about $0\text{ }^{\circ}\text{C}$ to about $+20\text{ }^{\circ}\text{C}$. The hydroborated product of this reaction may then be oxidatively removed to the alcohol

using alkaline hydrogen peroxide (See *Boranes in Organic Chemistry*, H. C. Brown, Cornell University Press, Ithaca, NY 1972, pp. 321-325), which may then be oxidized to either the aldehyde (W= H) or to the acid (W= OH) using methods known to one of ordinary skill in the art. Alternatively, the hydroborated product may be directly oxidized
5 to the aldehyde or acid by treatment with chromic acid or a Cr(VI) salt. Such salts include pyridinium chlorochromate (PCC) and dichlorochromate. See Brown, H. C.; Kulkarni, Rao, and Patil, *Tetrahedron*, 1986, 45515. The preferred method is treatment of the hydroborated product with PCC in dichloromethane at room temperature. The result of these manipulations is a compound of the type **S2a**.

10 The compound **S2a** is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, **S2a** is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent with 0.1% acetic acid added if W = OH.

15 The key intermediate aldehyde depicted as **S2a** can be reacted with a variety unsaturated carbon nucleophiles to provide the C-9 and C-11-protected 13,14-dihydro-16-tetranor prostaglandin F_{10} derivatives of **Formula III**.


With aromatic and heteroaromatic nucleophiles, the reaction is carried out preferably at between -80°C and 0°C, more preferably between -80°C and -20°C, and
20 most preferably between -80°C and -40°C. Preferred bases for the reaction include *n*-butyl lithium, *s*-butyl lithium, lithium diisopropylamide, and *t*-butyl lithium. The most preferred base is *n*-butyl lithium. Preferred solvents for the reaction are ether solvents. Preferred solvents include diethyl ether, and tetrahydrofuran. The most preferred solvent is tetrahydrofuran. With heterocyclic nucleophiles, preferred solvents include ethereal
25 solvents. More preferred ethereal solvents include diethyl ether, dibutyl ether and tetrahydrofuran. The most preferred ethereal solvent is tetrahydrofuran.

The resulting alcohol can be isolated, but is generally oxidized as a crude isolate. The oxidation of benzylic alcohols to benzylic ketones is well known in the art. The preferred reagents to effect this reaction include KMnO₄, MnO₂, chromic acid, Jones' reagent, Collins' reagent, and PCC. The most preferred method is oxidation at room
30 temperature in dichloromethane with PCC for about 4 hours. The ketones are isolated by column chromatography using 20% hexanes/ethyl acetate as solvent. The ester is then removed using standard conditions. See Greene and Wuts, *Protecting Groups in Organic Synthesis*, Wiley Interscience, NY pp.224-276. The free acid is then treated with 2.1
35 equivalents of a strong nitrogen base to effect deprotonation both of the acid and adjacent to the benzylic ketone. Such bases include LDA. This enolate is reacted with a

peroxidizing agent which has the effect of oxidizing the compound to deliver the alpha-hydroxy ketone. Such reagents include *meta* -chloroperoxybenzoic acid, dimethyl dioxirane, Davis' reagent and peracetic acid. The crude product may be isolated or the remaining protecting groups may be removed. At this point manipulation of the acid at C-1
5 may take place. For example, re-esterifying, making the amide, the hydroxamic acid or the sulfonamide using methods known to one of ordinary skill in the art may be performed to yield compounds according to **Formula III**. Compounds depicted by **Formula III** are exemplified in **Examples 21-30**.

Compounds depicted by **Formula IV** can be made from intermediate **S2b**. In this
10 case, condensation of the free acid is readily achieved with a variety of alcohols and amines, either by the use of coupling agents such as DCC, or by activating the acid with, for example, oxalyl chloride. Following this is the selective removal of the methyl esters as described in Greene and Wuts, *Protecting Groups in Organic Synthesis*, Wiley Interscience, NY pp.224-276, and the oxidation of the ester enolates using the same
15 technique described above for the ketone intermediates. Similarly, as described above, the remaining protecting groups are removed and the desired manipulation of C-1 is effected, yielding compounds of **Formula IV**. Compounds depicted by **Formula IV** are exemplified in **Examples 31-40**.

Scheme III



- 5 In **Scheme 3**, R_1 and Z are as defined above. The alkene **S1b** (from **Scheme 1**) is treated with an osmium salt and with an optional catalyst reoxidant, preferably *N*-methyl morpholine *N*-oxide (NMO), to give the diol. This diol is isolated by extraction and purified by silica gel chromatography. The diol is then oxidized selectively to the *alpha* hydroxy aldehyde. This may be accomplished in several ways. For example, a selective oxidant
- 10 such as DMSO-oxalyl chloride may be used. Alternatively, the primary alcohol may be selectively protected, then the secondary alcohol protected, then the protection on the primary alcohol may then be removed and the alcohol oxidized as described above in **Scheme II**. However, the preferred method is the addition of a *o*-bromo-benzyl bromide protecting group, which can be removed with concomitant oxidation by tributyl tin hydride
- 15 and like reagents. This technique yields compounds of the type **S3a**, wherein $\text{P} = \text{H}$. From this step follows the condensation of the aldehyde with an amine to form an imine of

the type **S3b**. Appropriate removal of protecting groups and manipulation of C-1 as stated above in **Schemes I** and **II** yields compounds according the **Formula V**. Compounds depicted by **Formula V** are exemplified in **Examples 41-48**.

5 The following non-limiting examples illustrate the compounds, compositions, and uses of the present invention.


Examples

Compounds are analyzed using ^1H and ^{13}C NMR, Elemental analysis, mass spectra, high resolution mass spectra and/or IR spectra as appropriate.

10 Typically, inert solvents are used, preferably in dried form. For example, tetrahydrofuran (THF) is distilled from sodium and benzophenone, diisopropylamine is distilled from calcium hydride and all other solvents are purchased as the appropriate grade. Chromatography is performed on silica gel (70-230 mesh; Aldrich) or (230-400 mesh; Merck) as appropriate. Thin layer chromatography analysis is performed on
15 glass mounted silica gel plates (200-300 mesh; J.T. Baker) and visualized using *uv* light, 5% phosphomolybdic acid in EtOH, or ammonium molybdate/ceric sulfate in 10% aqueous H_2SO_4 .

EXAMPLE 1

20 **Preparation of 13,14-dihydro-16-17-Z-didehydro-17-(2-fluorophenyl) prostaglandin $\text{F}_{1\alpha}$:**



- a. **Methyl 7-(2-oxo-4-(1,1,2,2-tetramethyl-1-silapropoxy)cyclopent-1-enyl) heptanoate (E1b):** To a solution of Methyl-7-[3-(R)-hydroxy-5-oxo-1-cyclopenten-1-yl] heptanoate **S1a** (1 equiv.) in CH₂Cl₂ at -78°C is added 2,6 Lutidine (1.3 equiv.) dropwise over 15 minutes. The solution is kept at -78°C. TBDMS Triflate (1.2 equiv.) in CH₂Cl₂ is added dropwise over 15 minutes. The reaction is warmed gradually to room temperature and stirred at room temperature for 15 hours. Aqueous 10% HCl is added and the layers are separated. The water layer is extracted with CH₂Cl₂ and the organic layers are combined. The organic layer is washed with brine, dried (Na₂SO₄) and concentrated. The residue is distilled under vacuum (10 mm Hg) to provide the silyl ether **E1b**.
- b. **Methyl 7-(5-but-3-enyl- 2-hydroxy-4- (1,1,2,2-tetramethyl-1-silapropoxy)cyclopentyl) heptanoate (E1c):** To a slurry of Mg⁰ powder (2 equiv.) in THF at room temperature is added one crystal of iodine (catalytic I₂) and 1-bromobutene (2 equiv.) dropwise over 10 minutes. The reaction proceeds to exotherm as the addition continues. After the addition is complete, the reaction is refluxed for 3 hours and cooled to room temperature. The Grignard is diluted with THF and added *via* cannula to a 3-necked flask equipped with mechanical stirring and charged with CuBr.DMS (2 equiv.) in a 1:1 solution of THF/DMS at -78°C. After the addition of the Grignard (~20 minutes), the reaction is stirred for 1 hour at -78°C. The color of the reaction is dark red at this

point. A solution of the ketone **E1b** (1 equiv.) in THF is then added dropwise over 25 minutes. The reaction is stirred at -78°C for 15 minutes, then allowed to warm slowly to room temperature over 2 hours. The reaction is quenched with aqueous NH₄Cl and the excess DMS is allowed to evaporate overnight. The reaction is partitioned between
5 brine/ CH₂Cl₂ and the layers are separated. The aqueous layer is back-extracted with CH₂Cl₂ and the organic layers are combined and dried (Na₂SO₄). The solvent is removed in vacuo and the residue is chromatographed on SiO₂ (10 % hexane/EtOAc) to give the ketone precursor to **E1c**.

The ketone precursor to **E1c** (1 equiv.) is dissolved in MeOH and cooled to -
10 40°C. Sodium borohydride (0.9 equiv.) is added portionwise over 10 minutes. After the addition is complete, the reaction is stirred for 13 hours at -40°C and then for 12 hours at -78°C. The reaction is quenched with water, partitioned between brine and CH₂Cl₂, and the layers separated. The aqueous layer is back-extracted with CH₂Cl₂ and the organic layers are combined and dried (Na₂SO₄). The solvent is removed in vacuo and
15 the residue chromatographed on SiO₂ (30 % EtOAc/hexanes) to give the alcohol **E1c**.

c. Methyl 7-(5-but-3-enyl -2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (E1d): The alcohol **E1c** (1 equiv.) is dissolved in CH₂Cl₂ and cooled to 0°C and 2,6 lutidine (1.3 equiv.) is added dropwise over 15 minutes. The solution is kept at -
20 78°C, and TBDMS Triflate (1.2 equiv.) in CH₂Cl₂ is added dropwise over 15 minutes. The reaction is warmed gradually to room temperature and stirred at room temperature for 15 hours. Aqueous 10% HCl is added and the layers are separated. The water layer is extracted with CH₂Cl₂ and the organic layers are combined. The organic layer is washed with brine, dried (Na₂SO₄) and concentrated. The residue is chromatographed
25 (10% EtOAc in hexanes) to provide the silyl ether **E1d**.

d. Methyl 7-(5-(3-oxopropanyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (E1e): In a 50 mL round-bottomed flask, sodium periodate (2 equiv.) and 10 mL of water are added. This is stirred until the periodate has completely
30 dissolved. Then an equal portion of glacial acetic acid is added, followed by two portions of tetrahydrofuran. Finally, a few mole percent of potassium osmate are added, followed by the alkene **E1d** (1 equiv.). The reaction is stirred at room temperature under nitrogen with TLC being used to monitor the reaction. When no starting material is evident by TLC, The reaction is quenched with brine and is extracted with ethyl acetate and
35 hexanes in a 4:1 ratio. The organic layer is washed with brine to neutral pH, dried over

sodium sulfate, and concentrated. After column chromatography, (7:3, Hexane: Ethyl Acetate) **E1e** is obtained.


e. **9,11-(1,1,2,2-tetramethyl-1-silapropoxy)-13,14-dihydro-16-17-didehydro-17-(o-fluoro-phenyl) prostaglandin F_{1α} E1f**: In a Round bottom flask is added chromium(II) chloride (2eq) and Nickel (II) chloride (.02 eq). DMF is added and the solution is stirred. To this is added alpha bromo-(o-fluoro)styrene (2eq) and the aldehyde (1eq). The reaction is monitored by TLC and then quenched with ammonium chloride when starting material is no longer present. The mixture is extracted into ethyl ether and washed with brine to neutral pH, dried with Magnesium sulfate, and concentrated. After column chromatography, (7:3, hexane: ethyl acetate) **E1f** is obtained.


f. **13,14-dihydro-16-17-Z-didehydro-17-(2-fluorophenyl) prostaglandin F_{1α} (E1g)**: To a small round-bottomed flask, is added methyl ester **E1f** and 3 mL of CH₃CN. Then 0.1 mL of HF/Pyridine (0.1 mmol, 1 equiv.) are added while the flask is warmed from 0°C to room temperature. After 3 hours at 21°C, the reaction is quenched with saturated aqueous NaCl. The aqueous layer is extracted three times with CH₂Cl₂. The organic layers are combined and washed three times with 1N HCl, brine, and dried (Na₂SO₄). After column chromatography (7:3, Hexane: Ethyl Acetate), a clear oil is obtained. This oil is added to a few mL of a 3:1 THF: water solution, and the flask is cooled to 0°C. An excess amount (2.5 equiv.) of lithium hydroxide is added, the ice bath is removed, and the reaction is stirred at room temperature overnight. Methylene chloride and saturated citric acid are added to the reaction mixture, the aqueous layer is washed 3 times with methylene chloride, the organic layers are combined and washed with brine, dried (Na₂SO₄), concentrated *in vacuo*, and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide **E1g**.

Examples 2-17


Examples 2-17 are prepared using substantially the same procedures as those described in **Example 1**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 2


13,14-dihydro-16-17-*E*-didehydro-17-(2-fluoro-phenyl)-17-trinor prostaglandin F_{1α}

Example 3**13,14-dihydro-*E*-16-17-didehydro-17-phenyl-17-trinor prostaglandin $F_{1\alpha}$** 

5

Example 4**13,14-dihydro-*E*-16-17-didehydro-17-(2,4-dichloro-phenyl)-17-trinor prostaglandin $F_{1\alpha}$** 

10


Example 5**13,14-dihydro-*E*-16-17-didehydro-17-(2-fluoro-4-methylphenyl)-17-trinor prostaglandin $F_{1\alpha}$** 

15

Example 6**13,14-dihydro-*E*-16-17-didehydro-17-(2-fluoro-5-chloro-phenyl)-17-trinor prostaglandin $F_{1\alpha}$**


20

22



Example 7


13,14-dihydro-*E*-16-17-didehydro-17-(2,5-difluoro-phenyl)-17-trinor prostaglandin $F_{1\alpha}$



5

Example 8


13,14-dihydro-*E*-16-17-didehydro-17-(2-fluoro-3-chloro-phenyl)-17-trinor prostaglandin $F_{1\alpha}$



10

Example 9

13,14-dihydro-*E*-16-17-didehydro-17-(2-fluoro-3-methoxy-phenyl)-17-trinor prostaglandin $F_{1\alpha}$





15


Example 10

13,14-dihydro-16-17-didehydro-17-(3-fluoro-phenyl)-17-trinor prostaglandin $F_{1\alpha}$


24

**Example 11****13,14-dihydro-16-17-didehydro-17-(4-fluoro-phenyl)-17-trinor prostaglandin F_{1α}**

5

Example 12**13,14-dihydro-*E*-16-17-didehydro-17-(3-trifluoromethyl-phenyl)-17-trinor prostaglandin F_{1α}**


10


Example 13**13,14-dihydro-16-17-dienyl-18-(phenyl)-18-dinor prostaglandin F_{1α}**

15


Example 14**13,14-dihydro-16-17-dienyl-18-(2-fluoro-phenyl)-18-dinor prostaglandin F_{1α}**

25





Example 15**13,14-dihydro-16-17-dienyl-18-(2,4-difluoro-phenyl)-18-dinor prostaglandin F_{1α}**

5

Example 16**13,14-dihydro-16-17-dienyl-18-(3-trifluoromethyl-phenyl)-18-dinor prostaglandin F_{1α}**

10

Example 17**13,14-dihydro-16-17-dienyl-18-(4-methoxy-phenyl)-18-dinor prostaglandin F_{1α}****Example 18****15 Preparation of 13,14-dihydro-16,17-alkenyl-17-(2-fluorophenyl)-17-trinor prostaglandin F1α 1-hydroxamic acid:**

In a flame-dried round-bottomed flask equipped with a magnetic stir bar is placed 13,14-dihydro-16,17-alkenyl-17-(2-fluorophenyl) trinor Prostaglandin $F_{1\alpha}$ methyl ester (**Example 1**) (1.0 equiv.) in methanol. To this solution is added hydroxylamine in methanol (1.25 equiv.). The solution stirred for a few minutes. The solution is then
5 treated with 1N hydrochloric acid and extracted with ethyl acetate. The organic layer is washed with brine, dried over anhydrous $MgSO_4$, filtered and concentrated under reduced pressure. The residue is purified by chromatography to give 13,14-dihydro-16,17-alkenyl-17-(2-fluorophenyl) trinor Prostaglandin $F_{1\alpha}$ 1-hydroxamic acid.


10

Examples 19-20


Examples 19-20 are prepared using substantially the same procedures as those described in **Example 18**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to
15 block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 19


20 **13,14-dihydro-15,16-dienyl-17-phenyl-17-trinor Prostaglandin $F_{1\alpha}$ 1-hydroxamic acid**

**Example 20**

25 **13,14-dihydro-16,17-alkenyl-17-(3-fluorophenyl)-17-trinor Prostaglandin $F_{1\alpha}$ 1-N-methanesulfonamide**



Example 21

13,14-dihydro-16-keto-17-phenyl-17-trinor Prostaglandin F_{1α}

5

a. Methyl 7-(5-(4-oxobutyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (E21a): In a 50 mL round-bottomed flask, Borane-dimethyl sulfide adduct (2 equiv.) and 10 mL of ethyl ether are added. This is stirred until the borane reagent has completely dissolved. The flask is cooled to 0°C and the alkene is added in portions. When the reaction is complete by TLC, the mixture is poured into a well-stirred solution of pyridinium chlorochromate (PCC) in dichloromethane. The reaction is stirred at room temperature under nitrogen with TLC monitoring of the reaction. When no

10

starting material is evident by TLC, the reaction is quenched with a saturated ammonium chloride solution and is extracted with ethyl acetate and hexanes in a 4:1 ratio. The organic layer is washed with brine to neutral pH, dried over sodium sulfate, and concentrated. After column chromatography, (1:1.5, Hexane: Ethyl Acetate) **E21a** is
5 obtained.

b. Methyl 7-(5-(4-hydroxy-4-phenylbutyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (E21b): To a 50 mL round bottom flask is added phenyl lithium (1 equiv.) in THF and it is cooled to - 78°C. To this flask is then added **E21a** in
10 THF and is stirred for 30 minutes. The reaction was monitored by TLC and then quenched with ammonium chloride when starting material was no longer present. The mixture is extracted into ethyl ether and washed with brine to neutral pH, dried over magnesium sulfate, and concentrated. After column chromatography, (7:3, hexane: ethyl acetate) **E21b** is obtained.

c. Methyl 7-(5-(4-oxo-4-phenylbutyl)- 2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (E21c): To a small round-bottomed flask is added methyl ester **E21b** and a portion of dichloromethane. Added slowly is PCC and activated sieves. The solution is stirred at room temperature and monitored by TLC until further oxidation
15 ceases. At this point, the crude material is filtered through Fluorosil, concentrated and chromatographed to separate the ketone from the residual alcohol. After column chromatography, (7:3, hexane: ethyl acetate) **E21c** is obtained.

d. 7-(5-(3-hydroxy-4-oxo-4-phenylbutyl)- 2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoic acid (E21d): The oil **E21c** is added to a few mL of a 3:1 THF: water solution, and the flask is cooled to 0°C. An excess amount (2.5 equiv.) of lithium hydroxide is added, the ice bath is removed, and the reaction is stirred at room temperature overnight. Methylene chloride and saturated citric acid are added to the reaction mixture, the aqueous layer is washed 3 times with methylene chloride, the
25 organic layers are combined and washed with brine, dried (Na₂SO₄), concentrated *in vacuo*, and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide the free acid which is then dissolved in THF and cooled to - 78°C. A THF solution containing 2.1 equivalents of LDA is added, followed by 2.2 equivalents of TMSCl. This is followed by 1.1 equivalents of *m*CPBA and the entire
30 reaction is allowed to warm to room temperature. An acidic workup ensues, followed by
35 extraction into a 3:1 mixture of ethyl acetate/hexane, yielding the hydroxy ketone **E21d**.

- e. **13,14-dihydro-16-keto-17-phenyl-17-trinor Prostaglandin F_{1α} (E21e):** To a small round-bottomed flask, are added acid E21d and a portion of CH₃CN and HF/Pyridine (0.1 mmol, 1 equiv.) while the flask is slowly warmed from 0°C to room temperature. After 3 hours at 21°C, the reaction is quenched with saturated aqueous NaCl. The aqueous layer is extracted three times with CH₂Cl₂. The organic layers are combined and washed three times with 0.1N HCl, brine, and dried (Na₂SO₄), and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide the final product.


10

Examples 22-27


- Examples 22-27** are prepared using substantially the same procedures as those described in **Example 21**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.


Example 22

- 20 **13,14-dihydro-16-keto-16-(3,5-difluorophenyl)-16-tetranor prostaglandin F_{1α}**


**Example 23**

- 25 **13,14-dihydro-16-oxo-16-(2-furanyl)-16-tetranor prostaglandin F_{1α}**




Example 24**13,14-dihydro-16-oxo, 16-(3-chloro-5-methylphenyl)-16-tetranor prostaglandin $F_{1\alpha}$** 


5

Example 25**13,14-dihydro-16-keto-16-(4-fluorobenzo[b]furan-2-yl)-16-tetranor prostaglandin $F_{1\alpha}$** 


10

Example 26**13,14-dihydro-16-oxo-16-(2-thianaphthyl)-16-tetranor prostaglandin $F_{1\alpha}$** 

15

Example 27**13,14-dihydro-16-oxo-17-(2-benzothiazolyl)-16-tetranor prostaglandin F_{1α}**

5

Example 28**Preparation of 13,14-dihydro-16-oxo-16-(2,4-difluorophenyl)-16-tetranor PGF_{1α} 1-hydroxamic acid:**

10 In a flame-dried 25 mL round-bottomed flask equipped with a magnetic stir bar is 13,14-dihydro-16,17-alkenyl-17-*o*-fluorophenyl trinor PGF_{1α} methyl ester (**Example 22**) (1.0 equiv.) in methanol. To this solution is added hydroxylamine in methanol (1.25 equiv.). The solution stirred for a few minutes. The solution is then treated with 1.0 N hydrochloric acid (HCl) and extracted twice with portions of ethyl acetate. The organic

15 layer is washed with brine, dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. The residue is purified by chromatography to is 13,14-dihydro-16,17-alkenyl-17-(2-fluorophenyl) trinor PGF_{1α} 1-hydroxamic acid.


Examples 29-30

20 **Examples 29-30** are prepared using substantially the same procedures as those described in **Example 28**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily

25 be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 29


13,14-dihydro-16-oxo-16-(4-methylphenyl)-16-tetranor Prostaglandin F_{1α} 1-hydroxamic acid



5


Example 30

13,14-dihydro-16-oxo,16- (2-thianaphthyl)-16-tetranor Prostaglandin F_{1α} 1-N-methanesulfonamide



10

Example 31

13,14-dihydro-15-(N-phenylcarbamoyl)-15-pentanor Prostaglandin F_{1α}

5 a. Methyl 7-(5-(4-carboxybutyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy)

cyclopentyl) heptanoate (E31a): In a 50 mL round-bottomed flask, compound E21a is added. There follows a titration with a neutral solution of potassium permanganate (KMnO_4). When the reaction is complete by TLC, the mixture is washed with saturated sodium citrate and extracted three times with dichloromethane. The organic layer is
 10 separated, dried over sodium sulfate, and concentrated. After column chromatography, (methylene chloride, methanol, acetic acid, 9:6: 0.4, 0.015), E31a is obtained.

b. Methyl 7-(5-(3-N-phenylcarbamyl-propyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (E31b): To a 50 mL round bottom flask is
 15 added aniline (1 equiv.) in THF, then dicyclohexylcarbodiimide (DCC) is added in excess. To this flask is then added E31a in THF and is stirred for 30 minutes. The reaction is monitored by TLC and slight heat is applied if necessary, then quenched with

ammonium chloride when starting material is no longer present. The mixture is extracted into ethyl ether and washed with brine to neutral pH, dried over magnesium sulfate, and concentrated. After column chromatography, (1:1, hexane: ethyl acetate) **E31b** is obtained.


5

d. 7-(5-(3-hydroxy-4-oxo-4-phenylbutyl)- 2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclo pentyl) heptanoic acid (E31c): **E31b** is added to a few mL of a 3:1 THF: water solution, and the flask is cooled to 0°C. An excess amount (2.5 equiv.) of lithium hydroxide is added, the ice bath is removed, and the reaction is stirred at room temperature overnight. Methylene chloride and saturated citric acid are added to the reaction mixture, the aqueous layer is washed three times with methylene chloride, the organic layers are combined and washed with brine, dried (Na₂SO₄), concentrated *in vacuo*, and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide the free acid which is then dissolved in THF and cooled to -78°C. A THF solution containing 2.1 equivalents of LDA is added, followed by 2.2 equivalents of TMSCl. This is followed by 1.1 equivalents of *m*CPBA and the entire reaction is allowed to warm to room temperature. An acidic workup ensues, followed by extraction into a 3:1 mixture of ethyl acetate/hexane, yielding the hydroxy amide **E31c**.


e. 13,14-dihydro-15-(N-phenylcarbamoyl)-15-pentanor Prostaglandin F₁α (E31d): To a small round-bottomed flask, are added acid **E31c** and a portion of CH₃CN and HF/Pyridine (0.1 mmol, 1 equiv.) while the flask is slowly warmed from 0°C to room temperature. After 3 hours at 21°C, the reaction is quenched with saturated aqueous NaCl. The aqueous layer is extracted three times with CH₂Cl₂. The organic layers are combined and washed three times with 0.1N HCl, brine, and dried (Na₂SO₄), and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide the final product.

Examples 32-37


Examples 32-37 are prepared using substantially the same procedures as those described in **Example 31**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.


Example 32**13,14-dihydro-15-(*N*-3,4-difluorophenylcarbamoyl)-15-pentanor prostaglandin F_{1α}**

5


Example 33**13,14-dihydro-15-(*N*-2-furanylcabamoyl)-15-pentanor prostaglandin F_{1α}**

10


Example 34**13,14-dihydro-15-(*N*-2-fluorophenylcarbamoyl)-15-pentanor prostaglandin F_{1α}**

Example 35**13,14-dihydro-15-(phenoxycarbonyl)-15-pentanor prostaglandin F_{1α}**

5

Example 36**13,14-dihydro-15-(2-fluorophenoxycarbonyl)-15-pentanor prostaglandin F_{1α}**

10

Example 37**13,14-dihydro-15-(3-trifluoromethylthiaphenoxycarbonyl)-15-pentanor prostaglandin F_{1α}**

15


Examples 38-40

Examples 38-40 are prepared using substantially the same procedures as those described in **Example 28**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily

be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.


Example 38

- Preparation of 13,14-dihydro-15-(*N*-3,4-difluorophenylcarbamoyl)-15-pentanoic acid
5 $\text{PGF}_{1\alpha}$ 1-hydroxamic acid:




Example 39

- 10 Preparation of 13,14-dihydro-15-(*N*-3-chlorophenylcarbamoyl)-15-pentanoic acid $\text{PGF}_{1\alpha}$ 1-hydroxamic acid:




Example 40

- 15 Preparation of 13,14-dihydro-15-(*N*-phenylcarbamoyl)-15-pentanoic acid $\text{PGF}_{1\alpha}$ 1-N methane sulfonamide:



Example 41

Preparation of 13,14-dihydro-17-aza-16-enyl-17-phenyl-17-trinor PGF_{1α}:

- 5 a. **Methyl 7-(5-(3-hydroxy-4-oxobutyl)butyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (E41a):** In a 50 mL round-bottomed flask, compound E21a is added, followed by a portion of methylene chloride (CH₂Cl₂). There follows addition of a slight molar excess of *meta*-chloroperoxybenzoic acid (*m*-CPBA) (Aldrich). When the reaction is complete by TLC, the mixture is washed with sodium sulfite solution, the organic layer is separated, is dried over sodium sulfate, and is concentrated. After column chromatography (20% EtOAc in hexanes), the epoxide as a clear oil is obtained. This oil is dissolved in DMSO and an equivalent of *o*-bromo-benzyl alcohol is added. This is heated to effect the nucleophilic opening of the epoxide by the alcohol. The material is added to a portion of brine and extracted exhaustively with a 3:1 mixture of ethyl acetate and hexanes. This material is chromatographed (10% EtOAc in hexanes) to provide the benzyl ether as an oil. The benzyl ether is then dissolved in benzene and a dilute solution of tri-*n*-butyl tin hydride is slowly added at the temperature increased to

reflux. More hydride is added if needed to ensure complete reaction. The aldehyde thus recovered, **E41a**, is carefully chromatographed on silica gel (20% EtOAc in hexanes).


5 **b. Methyl 7-(5-(5-aza-3-hydroxypent-4-enyl)-2,4-di(1,1,2,2-tetramethyl-1-silapropoxy) cyclopentyl) heptanoate (E41b):** To a 50 mL round bottom flask is added aniline (1 equiv.) in C_6H_6 , then **E41a**. The mixture is then heated and the water formed is removed by azeotropic distillation with a Dean-Stark trap. The reaction is monitored by TLC. The product is isolated by removal of the benzene *in vacuo*, and
10 column chromatography, (1:1, hexane: ethyl acetate) yields **E41b**.

c. 13,14-dihydro-17-aza-16-enyl-17-phenyl-17-trinor PGF_{1 α} (E41c): To a small round-bottomed flask, is added methyl ester **E41b** and a portion CH_3CN and HF/Pyridine (0.1 mmol, 1 equiv.) while the flask is slowly warmed from 0°C to room temperature. After 3
15 hours at 21°C, the reaction mixture is added to a silica gel chromatography column and chromatographed with 5% methanol in CH_2Cl_2 to yield the dihydroxy ester. This ester is saponified by adding it dropwise in methanol to a gently stirred aqueous solution of pig liver esterase (Sigma) buffered at pH =7. Care must be taken to ensure that the total concentration of the MeOH remains below 10% (v/v). When the reaction is complete by
20 TLC, the solution is acidified with citric acid, and is extracted three times with CH_2Cl_2 . The organic layers are combined and washed with brine, and dried (Na_2SO_4), and the residue is chromatographed (methylene chloride, methanol, acetic acid, 9.6, 0.4, 0.015), to provide the final product.


25

Examples 42-45


Examples 42-45 are prepared using substantially the same procedures as those described in **Example 41**, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to
30 block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

Example 42**13,14-dihydro-17-aza-16-enyl-17-(2-fluorophenyl)-17-trinor PGF_{1α}**


5

Example 43**13,14-dihydro-17-aza-16-enyl-17-(2-furanyl)-17-trinor prostaglandin F_{1α}**

10

Example 44**13,14-dihydro-17-aza-16-enyl-17-(4-phenylphenyl)-17-trinor prostaglandin F_{1α}**

15

Example 45**13,14-dihydro-17-aza-16-enyl-17-(3-fluorophenyl)-17-trinor prostaglandin F_{1α}**


Examples 46-48

Examples 46-48 are prepared using substantially the same procedures as those described in Example 28, substituting the appropriate starting materials. The skilled artisan may change temperature, pressure, atmosphere, solvents or the order of reactions as appropriate. Additionally, the skilled artisan may use protecting groups to block side reactions or increase yields as appropriate. All such modifications can readily be carried out by the skilled artisan in the art of organic chemistry, and thus are within the scope of the invention.

10

Example 46


Preparation of 13,14-dihydro-17-aza-16-enyl-17-(-2-furanyl)-17-trinor prostaglandin F_{1α} 1-hydroxamic acid




15

Example 47

Preparation of 13,14-dihydro-17-aza-16-enyl-17-(3-chlorophenyl)-17-trinor prostaglandin F_{1α} 1-hydroxamic acid



20

Example 48**Preparation of 13,14-dihydro-17-aza-16-enyl-17-(-2-thiofuranyl)-17-trinor prostaglandin F_{1α} 1-N-methanesulfonamide**

5

Compositions

Compositions of the subject invention comprise a safe and effective amount of the subject compounds, and a pharmaceutically-acceptable carrier. As used herein, "safe and effective amount" means an amount of a compound sufficient to significantly induce a positive modification in the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. A safe and effective amount of a compound will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the particular pharmaceutically-acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician.

In addition to the compound, the compositions of the subject invention contain a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier", as used herein, means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to a subject. The term "compatible", as used herein, means that the components of the composition are capable of being commingled with the compound, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations. Pharmaceutically-acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the subject being treated.

Some examples of substances which can serve as pharmaceutically-acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as cornstarch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate; powdered tragacanth;

malt; gelatin; talc; solid lubricants, such as stearic acid, magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the Tweens®; wetting agents such as sodium lauryl sulfate; coloring agents; flavoring agents, excipients; tableting agents; 5 stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.

The choice of a pharmaceutically-acceptable carrier to be used in conjunction with a compound is basically determined by the way the compound is to be 10 administered. The compounds of the present invention may be administered systemically. Routes of administration include transdermal; oral; parenterally, including subcutaneous or intravenous injection; topical; and/or intranasal.

The appropriate amount of the compound to be used may be determined by routine experimentation with animal models. Such models include, but are not limited to 15 the intact and ovariectomized rat models, the ferret, canine, and non human primate models as well as disuse models.

Preferred unit dosage forms for injection include sterile solutions of water, physiological saline, or mixtures thereof. The pH of said solutions should be adjusted to about 7.4. Suitable carriers for injection or surgical implants include hydrogels, 20 controlled- or sustained release devices, polylactic acid, and collagen matrices.

Suitable pharmaceutically-acceptable carriers for topical application include those suited for use in lotions, creams, gels and the like. If the compound is to be administered perorally, the preferred unit dosage form is tablets, capsules and the like. The pharmaceutically-acceptable carriers suitable for the preparation of unit dosage 25 forms for oral administration are well-known in the art. Their selection will depend on secondary considerations like taste, cost, and shelf stability, which are not critical for the purposes of the subject invention, and can be made without difficulty by those skilled in the art.

30 **Methods of Use**

The compounds of the present invention are useful in treating many medical disorders, including for example, ocular disorders, hypertension, fertility control, nasal congestion, neurogenic bladder disorder, gastrointestinal disorders, dermatological disorders, and osteoporosis.

35 The compounds of the present invention are useful in increasing bone volume and trabecular number through formation of new trabeculae, bone mass while

maintaining a normalized bone turnover rate, and formation at the endosteal surface without removing bone from the existing cortex. Thus, these compounds are useful in the treatment and prevention of bone disorders.

5 The preferred routes of administration for treating bone disorders are transdermal and intranasal. Other preferred routes of administration include rectal, sublingual, and oral.

The dosage range of the compound for systemic administration is from about 0.01 to about 1000 $\mu\text{g/kg}$ body weight, preferably from about 0.1 to about 100 $\mu\text{g/kg}$ per body weight, most preferably from about 1 to about 50 $\mu\text{g/kg}$ body weight per day. The
10 transdermal dosages will be designed to attain similar serum or plasma levels, based upon techniques known to those skilled in the art of pharmacokinetics and transdermal formulations. Plasma levels for systemic administration are expected to be in the range of 0.01 to 100 nanograms/ml, more preferably from 0.05 to 50 ng/ml, and most preferably from 0.1 to 10 ng/ml. While these dosages are based upon a daily
15 administration rate, weekly or monthly accumulated dosages may also be used to calculate the clinical requirements.

Dosages may be varied based on the patient being treated, the condition being treated, the severity of the condition being treated, the route of administration, etc. to achieve the desired effect.

20 The compounds of the present invention are also useful in decreasing intraocular pressure. Thus, these compounds are useful in the treatment of glaucoma. The preferred route of administration for treating glaucoma is topically.

Composition and Method Examples

25 The following non-limiting examples illustrate the subject invention. The following composition and method examples do not limit the invention, but provide guidance to the skilled artisan to prepare and use the compounds, compositions and methods of the invention. In each case other compounds within the invention may be substituted for the example compound shown below with similar results. The skilled practitioner will
30 appreciate that the examples provide guidance and may be varied based on the condition being treated and the patient.

Example A

Pharmaceutical compositions in the form of tablets are prepared by conventional methods, such as mixing and direct compaction, formulated as follows:

	<u>Ingredient</u>	<u>Quantity (mg per tablet)</u>
5	Compound of Example 1	5
	Microcrystalline Cellulose	100
	Sodium Starch Glycollate	30
	Magnesium Stearate	3

- 10 When administered orally once daily, the above composition substantially increases bone volume in a patient suffering from osteoporosis.

Example B

Pharmaceutical compositions in liquid form are prepared by conventional methods, formulated as follows:

	<u>Ingredient</u>	<u>Quantity</u>
15	Compound of Example 32	1 mg
	Phosphate buffered physiological saline	10 ml
	Methyl Paraben	0.05ml

- 20 When 1.0 ml of the above composition is administered subcutaneously once daily, the above composition substantially increases bone volume in a patient suffering from osteoporosis.

Example C


- 25 Topical pharmaceutical compositions for lowering intraocular pressure are prepared by conventional methods and formulated as follows:

	<u>Ingredient</u>	<u>Amount (wt %)</u>
	Compound of Example 1	0.004
	Dextran 70	0.1
	Hydroxypropyl methylcellulose	0.3
30	Sodium Chloride	0.77
	Potassium chloride	0.12
	Disodium EDTA (Edetate disodium)	0.05
	Benzalkonium chloride	0.01
	HCL and/or NaOH	pH 7.2-7.5
35	Purified water	q.s. to 100%

While particular embodiments of the subject invention have been described, it would be obvious to those skilled in the art that various changes and modifications to the compositions disclosed herein can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications
5 that are within the scope of this invention.

What is claimed is:

1. A compound having the structure:



wherein

- (a) R_1 is selected from the group consisting of CO_2H , C(O)NHOH , CO_2R_2 , CH_2OH , $\text{S(O)}_2\text{R}_2$, C(O)NHR_2 , $\text{C(O)NHS(O)}_2\text{R}_2$, or tetrazole; wherein R_2 is alkyl, heteroalkyl, carbocyclic aliphatic ring, heterocyclic aliphatic ring, monocyclic aromatic ring, or monocyclic heteroaromatic ring and R_3 is lower alkyl, lower heteroalkyl, or haloalkyl. Preferred R_2 is methyl, ethyl, and isopropyl;
 - (b) X is:
 - (1) $\text{CH}=\text{C}=\text{CH}$
 - (2) $\text{CH}=\text{CH}$
 - (3) $\text{CH}=\text{N}$
 - (4) C(O)
 - (5) C(O)Y ; wherein Y is selected from the group consisting of O, S, and NH;
 - (c) Z is an aromatic ring or a heteroaromatic ring provided that when Z is a heteroaromatic ring Z is attached via a Carbon member atom; and
 - (d) any optical isomer, diastereomer, enantiomer of the above structure or a pharmaceutically-acceptable salt, or bio-hydrolyzable amide, ester, or imide thereof.
2. A compound according to Claim 1 wherein X is $\text{CH}=\text{C}=\text{CH}$ or C(O)Y .
 3. A compound according to Claim 2 wherein Z is monocyclic.
 4. A compound according to Claim 1 wherein X is $\text{CH}=\text{CH}$, $\text{CH}=\text{N}$, or C(O) .
 5. A compound according to Claim 4 wherein Z is bicyclic.
 6. A compound according to any of the preceding claims characterized in that R_1 is CO_2H , C(O)NHOH , CO_2R_2 , $\text{C(O)NHS(O)}_2\text{R}_2$, or tetrazole.
 7. A compound according to any of the preceding claims characterized in that Z substituted with one substituent, said one substituent being selected from the group consisting of: lower alkyl, halo, and haloalkyl.

8. The use of a compound according to any of the preceding claims in the manufacture of a medicament for treating a bone disorder.
9. The use according to claim 8 characterized in that the bone disorder is osteoporosis.
10. The use of a compound according to Claims 1, 2, 3, 4, 5, 6, or 7 in the manufacture of a medicament for treating glaucoma.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/05299

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C405/00 //A61K31/557

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR 2 314 712 A (ONO PHARMACEUTICAL CO) 14 January 1977 (1977-01-14) claims	1-10
Y	US 5 480 900 A (DESANTIS JR LOUIS ET AL) 2 January 1996 (1996-01-02) claims	1-10
P, X	WO 99 12551 A (PROCTER & GAMBLE) 18 March 1999 (1999-03-18)	1-10
Y	claims 1,12,15	1-10
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 July 2000

Date of mailing of the international search report

28/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/05299

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FALL, PAMELA M. ET AL: "Inhibition of collagen synthesis by prostaglandins in the immortalized ra osteoblastic cell line Pyla: Structure-activity relations and signal transduction mechanisms" retrieved from STN Database accession no. 122:46727 XP002142455 abstract & J. BONE MINER. RES. (1994), 9(12), 1935-43 ,</p> <p style="text-align: center;">-----</p>	

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 00/05299

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2314712 . A	14-01-1977	GB 1520522 A	09-08-1978
		DE 2622123 A	30-12-1976
		JP 51149247 A	22-12-1976
		US 4018812 A	19-04-1977

US 5480900 A	02-01-1996	US 5605922 A	25-02-1997
		US 5811443 A	22-09-1998
		AT 153855 T	15-06-1997
		AU 674038 B	05-12-1996
		AU 5328694 A	09-05-1994
		DE 69311361 D	10-07-1997
		DE 69311361 T	08-01-1998
		EP 0664707 A	02-08-1995
		ES 2105333 T	16-10-1997
		HK 1007102 A	01-04-1999
		JP 3002258 B	24-01-2000
		JP 8502485 T	19-03-1996
		WO 9408585 A	28-04-1994

WO 9912551 A	18-03-1999	AU 9219298 A	29-03-1999
		NO 20001171 A	09-05-2000
		ZA 9808228 A	09-03-1999
